ライフサイエンスコーパス: portosystemic shunt

1 oes not preclude the creation of nonsurgical portosystemic shunt.

2 ion or stenosis and the presence of a patent portosystemic shunt.

3 ter placement of a transjugular intrahepatic portosystemic shunt.

4 erance of liver to warm ischemia injury with portosystemic shunt.

5 is increase was significantly reversed after portosystemic shunt.

6 Five had variceal bleeding, and 2 had portosystemic shunts.

7 , liver transplants, choledocholithiasis, or portosystemic shunts.

8 ctive placement of transjugular intrahepatic portosystemic shunts.

9 r, eNOS (-/-) mice did develop a substantial portosystemic shunt (0.33% +/- 0.005% vs 84.53% +/- 0.19

10 2 +/- 0.003 vs 0.227 +/- 0.005 mL/min/g) and portosystemic shunt (0.47% +/- 0.01% vs 84.13% +/- 0.09%

11 Two patients had an extrahepatic portosystemic shunt, 17 had a portacaval shunt [subdivid

12 band ligation and transjugular intrahepatic portosystemic shunt, almost every acute variceal bleed c

13 evaluate race as a predictor of undergoing a portosystemic shunt and LT and of dying in the hospital.

14 th vehicle, JWH-015 significantly alleviated portosystemic shunting and mesenteric vascular density i

15 s alternative treatment options to operative portosystemic shunts and devascularization procedures.

16 Despite these innovations, portosystemic shunts and esophagogastric devascularizati

17 us-1, previous LT, transjugular intrahepatic portosystemic shunt, and acute dialysis at LT.

18 Large spontaneous portosystemic shunts are associated significantly with m

19 Transjugular intrahepatic portosystemic shunts are frequently used in patients wit

20 be successfully used as a bridge to surgical portosystemic shunting, as well as liver transplantation

21 e hepatocytes after liver warm ischemia with portosystemic shunt, compared with liver ischemia withou

22 creased patency at transjugular intrahepatic portosystemic shunt creation.

23 Ppv), abdominal aortic blood flow (Qao), and portosystemic shunt determined 2 weeks later.

24 The indications for and the results of portosystemic shunts done in the authors' institution si

25 Portosystemic shunt enhances the tolerance of liver to w

26 Liver disease or portosystemic shunting enhances th e sensitivity to endo

27 Spontaneous portosystemic shunts greater than 10 mm in diameter, ide

28 All extrahepatic portosystemic shunts, H-type portal-caval, portohepatic,

29 Transjugular intrahepatic portosystemic shunt has become an accepted intervention

30 g and placement of transjugular intrahepatic portosystemic shunts, have improved preoperative assessm

31 modalities such as transjugular intrahepatic portosystemic shunting, hemodialysis, and in some cases,

32 paracentesis with transjugular intrahepatic portosystemic shunt in the management of refractory asci

33 iography, which disclosed virtually complete portosystemic shunting in Fut2(-/-)(high) mice, discrete

34 c shunting in Fut2(-/-)(high) mice, discrete portosystemic shunting in Fut2(-/-)(low) mice, and no sh

35 ler hepatocyte size is the result of massive portosystemic shunting in null animals.

36 ocumented the frequency of large spontaneous portosystemic shunts in patients with moderate or severe

37 A transjugular intrahepatic portosystemic shunt is indicated when control of the ref

38 Transjugular intrahepatic portosystemic shunts may be helpful in the treatment of

39 amics, presence of CB receptors, severity of portosystemic shunting, mesenteric vascular density, vas

40 outflow obstruction classically treated with portosystemic shunts or liver transplantation.

41 Early transjugular intrahepatic portosystemic shunts placed in highly selected patients

42 vein embolization, transjugular intrahepatic portosystemic shunt placement, balloon retrograde transv

43 The transjugular intrahepatic portosystemic shunt procedure is an effective interventi

44 who underwent the transjugular intrahepatic portosystemic shunt procedure.

45 ation or undergoing transvenous intrahepatic portosystemic shunt procedures.

46 ic artery flow, mesenteric vascular density, portosystemic shunting (PSS), intrahepatic angiogenesis,

47 urements, including portal pressure (PP) and portosystemic shunts (PSS), and collected tissues for hi

48 A modified transjugular intrahepatic portosystemic shunt puncture set was introduced from the

49 t2(-/-) mice is dominated by consequences of portosystemic shunting resulting in microcirculatory dis

50 150 min liver warm ischemia with or without portosystemic shunt (splenic-caval shunt).

51 Large spontaneous portosystemic shunts (SPSSs) have been previously sugges

52 ve been treated by transjugular intrahepatic portosystemic shunt, surgical exploration, or peritoneov

53 Transjugular intrahepatic portosystemic shunt (TIPS) and surgical distal splenoren

54 lity and safety of transjugular intrahepatic portosystemic shunt (TIPS) as a treatment for BCS with d

55 thoracentesis and transjugular intrahepatic portosystemic shunt (TIPS) as second-line therapeutic op

56 ter placement of a transjugular intrahepatic portosystemic shunt (TIPS) correlates with the absence o

57 ailure (ELF) after transjugular intrahepatic portosystemic shunt (TIPS) creation in patients with cir

58 d complications of transjugular intrahepatic portosystemic shunt (TIPS) creation performed by using a

59 and bare stent in transjugular intrahepatic portosystemic shunt (TIPS) for cirrhotic portal hyperten

60 ibe the results of transjugular intrahepatic portosystemic shunt (TIPS) for the management of VOD aft

61 Recently, transjugular intrahepatic portosystemic shunt (TIPS) has been compared with ET in

62 the placement of a transjugular intrahepatic portosystemic shunt (TIPS) has been reported in up to 10

63 on human patients, transjugular intrahepatic portosystemic shunt (TIPS) has been worldwide considered

64 ients treated with transjugular intrahepatic portosystemic shunt (TIPS) have lower rebleeding rates c

65 s, and efficacy of transjugular intrahepatic portosystemic shunt (TIPS) in a series of patients with

66 Transjugular intrahepatic portosystemic shunt (TIPS) in patients with portal hyper

67 cacy and safety of transjugular intrahepatic portosystemic shunt (TIPS) in this population are unknow

68 The transjugular intrahepatic portosystemic shunt (TIPS) is an important treatment for

69 Transjugular intrahepatic portosystemic shunt (TIPS) is performed to treat some co

70 Transjugular intrahepatic portosystemic shunt (TIPS) is used in the management of

71 ansplantation, and transjugular intrahepatic portosystemic shunt (TIPS) on patient selection and outc

72 The effects of transjugular intrahepatic portosystemic shunt (TIPS) on portal hemodynamics, esoph

73 ty and efficacy of transjugular intrahepatic portosystemic shunt (TIPS) performed semiemergently and

74 disease underwent transjugular intrahepatic portosystemic shunt (TIPS) placement for control of vari

75 Transjugular intrahepatic portosystemic shunt (TIPS) placement is effective in the

76 w before and after transjugular intrahepatic portosystemic shunt (TIPS) placement.

77 nts undergoing the transjugular intrahepatic portosystemic shunt (TIPS) procedure in patient groups w

78 cations related to transjugular intrahepatic portosystemic shunt (TIPS) stents found in the portal ve

79 converting failed transjugular intrahepatic portosystemic shunt (TIPS) to distal splenorenal shunt (

80 canalization (PVR)-transjugular intrahepatic portosystemic shunt (TIPS) to potentiate LT.

81 Additional transjugular intrahepatic portosystemic shunt (TIPS) was created to facilitate the

82 The transjugular intrahepatic portosystemic shunt (TIPS) was developed in the 1980s fo

83 ble on the role of transjugular intrahepatic portosystemic shunt (TIPS) with covered stents in patien

84 ainly treated with transjugular intrahepatic portosystemic shunt (TIPS).

85 for creation of a transjugular intrahepatic portosystemic shunt (TIPS).

86 atients undergoing transjugular intrahepatic portosystemic shunt (TIPS).

87 ant and five had a transjugular intrahepatic portosystemic shunt (TIPS).

88 paracentesis, and transjugular intrahepatic portosystemic shunt (TIPS)], but refractory hydrothorax

89 ility, before/after transvenous intrahepatic portosystemic shunting (TIPS), and before/after yogurt t

90 catheter-directed thrombolysis, transjugular portosystemic shunting (TIPS), and liver transplantation

91 asty/thrombolysis, transjugular intrahepatic portosystemic shunting (TIPS), and orthotopic liver tran

92 Transjugular intrahepatic portosystemic shunts (TIPS) are a recent innovation in t

93 Transjugular intrahepatic portosystemic shunts (TIPS) are sometimes used to reduce

94 after creation of transjugular intrahepatic portosystemic shunts (TIPS) has been attributed to hemol

95 re of infection of transjugular intrahepatic portosystemic shunts (TIPS) has not been described previ

96 Transjugular intrahepatic portosystemic shunts (TIPS) have widened the use of port

97 ts with the use of transjugular intrahepatic portosystemic shunts (TIPS) in the treatment of these pa

98 Transjugular intrahepatic portosystemic shunts (TIPS) is a second-line treatment b

99 ectasia (GVE), to transjugular intrahepatic portosystemic shunts (TIPS) is not known.

100 Transjugular intrahepatic portosystemic shunts (TIPS) lower portal pressure and ha

101 Transjugular intrahepatic portosystemic shunts (TIPS) may worsen liver function an

102 ver the ability of transjugular intrahepatic portosystemic shunts (TIPS) to increase survival times o

103 ver the ability of transjugular intrahepatic portosystemic shunts (TIPS) to increase survival times o

104 linical utility of transjugular intrahepatic portosystemic shunts (TIPS) vis-a-vis total paracentesis

105 (CT) angiograms of transjugular intrahepatic portosystemic shunts (TIPS), helical CT angiography was

106 ing the patency of transjugular intrahepatic portosystemic shunts (TIPS).

107 Models described in rats using portosystemic shunts to achieve total ischemia have been

108 previously placed transjugular intrahepatic portosystemic shunt underwent successful liver transplan

109 andomized trial of transjugular intrahepatic portosystemic shunt using covered stents and another pil

110 with subsequent guidewire snaring to perform portosystemic shunting via femoral access.

111 A transjugular intrahepatic portosystemic shunt was created in 14 young swine (weigh

112 Portosystemic shunting was demonstrated by portal angiog

113 Portosystemic shunting was shown by radiological methods

114 tes, the adjusted odds ratios of receiving a portosystemic shunt were 0.37 (95% CI: 0.27-0.51) and 0.

115 l stenosis and the presence of a spontaneous portosystemic shunt whose successful endovascular treatm